After Maxim Group and H.C. Wainwright gave Actinium Pharmaceuticals (NYSE MKT: ATNM) a Buy rating last month, the company received another Buy, this time from JonesTrading. Analyst Soumit Roy reiterated a Buy rating on Actinium Pharmaceuticals today and set a price target of $22.00. The company's shares closed last Wednesday at $6.14. According to TipRanks.com, Roy is a 4-star analyst with an average return of 6.3% and a 30.0% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Monopar Therapeutics Inc. Actinium Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $30.67, representing a 389.9% upside.
https://www.tipranks.com/news/blurbs/actinium-pharmaceuticals-atnm-received-its-third-buy-in-a-row?utm_source=advfn.com&utm_medium=referral